JP7748715B2 - 線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物 - Google Patents

線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物

Info

Publication number
JP7748715B2
JP7748715B2 JP2021574140A JP2021574140A JP7748715B2 JP 7748715 B2 JP7748715 B2 JP 7748715B2 JP 2021574140 A JP2021574140 A JP 2021574140A JP 2021574140 A JP2021574140 A JP 2021574140A JP 7748715 B2 JP7748715 B2 JP 7748715B2
Authority
JP
Japan
Prior art keywords
fgf21
preference
sorbitol
carbohydrate
tagatose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021574140A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021153718A1 (https=
Inventor
努 佐々木
翔 松居
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JPWO2021153718A1 publication Critical patent/JPWO2021153718A1/ja
Application granted granted Critical
Publication of JP7748715B2 publication Critical patent/JP7748715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021574140A 2020-01-31 2021-01-29 線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物 Active JP7748715B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020015325 2020-01-31
JP2020015325 2020-01-31
PCT/JP2021/003182 WO2021153718A1 (ja) 2020-01-31 2021-01-29 線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物

Publications (2)

Publication Number Publication Date
JPWO2021153718A1 JPWO2021153718A1 (https=) 2021-08-05
JP7748715B2 true JP7748715B2 (ja) 2025-10-03

Family

ID=77079412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021574140A Active JP7748715B2 (ja) 2020-01-31 2021-01-29 線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物

Country Status (2)

Country Link
JP (1) JP7748715B2 (https=)
WO (1) WO2021153718A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101563A1 (en) 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
WO2008059625A1 (fr) 2006-11-17 2008-05-22 National University Corporation Kagawa University Utilisation de la fonction de sucre rare en tant que promoteur de la migration de glucokinase depuis le noyau jusqu'au cytoplasme
WO2008120813A1 (ja) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
JP2009286703A (ja) 2008-05-27 2009-12-10 Matsutani Chem Ind Ltd Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101563A1 (en) 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
WO2008059625A1 (fr) 2006-11-17 2008-05-22 National University Corporation Kagawa University Utilisation de la fonction de sucre rare en tant que promoteur de la migration de glucokinase depuis le noyau jusqu'au cytoplasme
WO2008120813A1 (ja) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
JP2009286703A (ja) 2008-05-27 2009-12-10 Matsutani Chem Ind Ltd Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤

Also Published As

Publication number Publication date
WO2021153718A1 (ja) 2021-08-05
JPWO2021153718A1 (https=) 2021-08-05

Similar Documents

Publication Publication Date Title
JP5633952B2 (ja) Ｄ−プシコースを有効成分とするグルコキナーゼの核から細胞質への移行の促進剤
KR100868529B1 (ko) 희소당의 생리활성 작용의 이용방법 및 희소당을 배합한조성물
AU2009283171B2 (en) Hydroxybutyrate ester and medical use thereof
US20100150890A1 (en) Medicinal composition, food or drink having effect of enhancing sympathetic nervous activity
EP2143719A1 (en) Pharmaceutical composition, food or beverage capable of enhancing sympathetic nerve activity
JP5705898B2 (ja) 肝機能改善剤
JP5545692B2 (ja) キサンチンオキシダーゼ阻害剤及び血漿中尿酸値低下剤
US20160279156A1 (en) Composition for preventing or treating colon cancer, containing 3,6-anhydrol-galactose
JP7748715B2 (ja) 線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物
JP2000217546A (ja) マンノース含有ヘテロオリゴ糖からなる甘味剤、病原菌感染抑制剤、整腸剤又は澱粉の老化抑制剤及び該剤からなる飲食品、医薬品又は飼料。
JP2016190801A (ja) 難消化性グルカンを含有する血中中性脂肪上昇抑制剤および血中レムナント様リポ蛋白コレステロール上昇抑制剤
JP2020188689A (ja) Ｔｏｘｉｃ ＡＧＥｓ生成抑制剤
JP2023154540A (ja) 加齢性難聴の予防又は改善のための組成物
JP2007051135A (ja) Ｄ−アロースの血糖上昇抑制効果の利用
JP2010059105A (ja) 炎症性腸疾患の予防又は治療剤
KR102588274B1 (ko) D-리모넨을 유효성분으로 포함하는 뇌전증 또는 발작 관련 질환의 예방 또는 치료용 약제학적 조성물
WO2021177335A1 (ja) 脳機能改善用組成物
JP6711539B2 (ja) 難消化性グルカンを含有する血糖上昇抑制剤およびその用途
JP2004269374A (ja) 血糖降下組成物
KR102415692B1 (ko) 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물
JP2019172614A (ja) 遺伝子発現制御剤及び筋委縮の抑制剤、予防剤又は改善剤
WO2024075625A1 (ja) 視野欠損障害、光誘発眼組織障害およびその関連障害の予防剤、進行防止剤、改善剤、並びに食品
CA2590369A1 (en) Compositions comprising sclareol or derivatives thereof and uses thereof
JP2024109822A (ja) アトロジン－１発現抑制剤
CN119792322A (zh) 没食子儿茶素没食子酸酯和异槲皮苷的用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250912

R150 Certificate of patent or registration of utility model

Ref document number: 7748715

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150